| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/24/2005 | WO2003037400A3 Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo |
| 02/24/2005 | WO2003018758A3 Reagents and methods for smooth muscle therapies |
| 02/24/2005 | US20050044582 Novel polynucleotides and uses therefor |
| 02/24/2005 | US20050043788 Drug-eluting stent |
| 02/24/2005 | US20050043525 Nucleotide sequences coding amidotransferase for use in identifying modulator for use in identifying microbiocides, fungicides and/or herbicidal agents |
| 02/24/2005 | US20050043520 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/24/2005 | US20050043518 Monoclonal antibody for use in detection of plant protein associated with natural rubber; diagnosing latex allergies and hypersensitivity |
| 02/24/2005 | US20050043511 G-protein coupled receptor lustr2 and uses thereof |
| 02/24/2005 | US20050043509 Peptoid compounds |
| 02/24/2005 | US20050043508 Synthetic peptide having an ionophoric and antimicrobial activity |
| 02/24/2005 | US20050043481 Material consisting of at least a biodegradable polymer and cyclodextrins |
| 02/24/2005 | US20050043386 2-amino-2-(ethyl or methyl)-4-{5-substituted pyrrol-2-yl}butan-1-ols, phosphates and phosphonates; antiarthritic agents; psoriasis; immunosuppressants |
| 02/24/2005 | US20050043367 Polyamine compounds are used to mobilize and harvest CD34+ cells via apheresis with and without combinations with other mobilizing factors; bind to chemokine receptors; regeneration of heart tissue |
| 02/24/2005 | US20050043313 1-(phenylaminocarbonylmethyl)-3-alkylamino-5,6-disubstituted-2-pyazinones; serine protease inhibitors; anticoagulants; coronary artery and cerebrovascular diseases |
| 02/24/2005 | US20050043297 Farnesyl dibenzodiazepinone, processes for its production and its use as a pharmaceutical |
| 02/24/2005 | US20050043273 Compositions and methods for inhibiting slit protein and glypican interactions |
| 02/24/2005 | US20050043267 Methods and compositions for inhibiting the function of polynucleotide sequences |
| 02/24/2005 | US20050043266 Hepatitis virus C genome is a single-stranded RNA that functions as both a messenger RNA and replication template, making it an attractive target for the study of RNA interference; double-stranded short interfering RNA molecules designed to target the HCV genome |
| 02/24/2005 | US20050043264 Abelson tyrosine kinase (Abl) actively participates in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease. Inhibiting Abl abrogates both activation of cyclin-dependent kinase 5 and its translocation in neurons expressing A beta 42 |
| 02/24/2005 | US20050043258 Contacting a salivary gland cell of a mammal with a protein selected from IFN-alpha, IL-10, sTNFR, TGF- beta , IL-4 and VIP, anti-TNF antibody, IL1-RA, other antibodies to proinflammatory cytokines, soluble gp39, soluble CD40, aquaporin-1 and aquaporin |
| 02/24/2005 | US20050043257 administration of siRNA directed to IKK alpha to cells and SiRNA can be 21 to 25 nucleotides in length and hybridize to a nucleic acid molecule encoding human IKK alpha; for treating autoimmune and inflammatory disease in a mammal |
| 02/24/2005 | US20050043256 antisense oligonucleotides, are targeted to a nucleic acid encoding stearoyl-CoA desaturase, and modulate the expression of stearoyl-CoA desaturase; gene therapy; genetic engineering; for treatment of abnormal lipid metabolism, obesity |
| 02/24/2005 | US20050043246 Acyclovir-peptide analogs |
| 02/24/2005 | US20050043245 Chicken II GnRH decapeptide analog having sequence p-Glu-His-Trp-Ser-His-Xaa1-Trp-Tyr-Pro-Xaa2, capable of binding to GnRH receptors within immune system and active in presence of post-proline peptidase or endopeptidase, comprising D-amino acid substitution at position 6 and amide at 10; immune disorders |
| 02/24/2005 | US20050043244 Sulfur compounds such as 4-(N-(1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)hydrazin-2-yl-carbonayl)-N -methyaminomethyl)phenyl oxycarbonyl-glutamic acid, used as sulfonyl hydrazine prodrugs(SHPs) having antitumor activity in mammals |
| 02/24/2005 | US20050043243 Polypeptide for use in treatment of energy balance defects, energy balance involving energy metabolism, nutritional state, lipid storage and the like, food intake and metabolism of carbohydrates and lipids to generate energy |
| 02/24/2005 | US20050043242 Using dietary restriction to lower serum insulin levels and function along with troglitazone in treatment and prevention of alzheimer's diseases |
| 02/24/2005 | US20050043241 Use of inhibitors of given amino acid sequence; inhibit phosphorylation of a transcription factor; can be used to treat or prevent diabetes, ionizing radiation damage, autoimmune diseases, ischemia/reperfusion injuries, heart hypertrophies, cancer |
| 02/24/2005 | US20050043240 Methods of reducing visceral fat by increasing levels of insulin-like growth factor-I (IGF-I) |
| 02/24/2005 | US20050043238 Exendin formulations for weight reduction |
| 02/24/2005 | US20050043237 Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use |
| 02/24/2005 | US20050043236 Nucleic acids; fusion proteins; binding to endothelial growth factor; fusion polypeptides capable of binding vascular endothelial cell growth factor (VEGF), VEGF family members, and splice variants with specifically desirable characteristics; therapy for ocular diseases |
| 02/24/2005 | US20050043235 Use of VEGF-C or VEGF-D in reconstructive surgery |
| 02/24/2005 | US20050043234 Novel FGF homologs |
| 02/24/2005 | US20050043232 Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| 02/24/2005 | US20050043231 Therapy for growth hormone induced insulin resistance in juveniles with growth disorders |
| 02/24/2005 | US20050043230 Use of long pentraxin ptx3 for the treatment of fgf-8 mediated tumour diseases |
| 02/24/2005 | US20050043229 Amino acid sequences of human secreted peptides and proteins that are related to the epidermal growth factor protein subfamily, as well as allelic variants and other mammalian orthologs thereof; for use in human therapeutics and diagnostics |
| 02/24/2005 | US20050043228 Glp-1 formulations with protracted time action |
| 02/24/2005 | US20050043226 having a building unit containing one nitrogen atom of the peptide backbone connected to a bridging group comprising an amide, thioether, thioester, or disulfide; used to treat cancers, diabetes, diabetic-associated complications, endocrine disorders, gastrointestinal disorders, and pancreatitis |
| 02/24/2005 | US20050043223 Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility |
| 02/24/2005 | US20050043221 Stabilizing collagen VI-deficient dystrophin-associated protein complexes (DAPCs) on the surface of a cell by contacting the cell with an effective amount of a biglycan therapeutic; treatment of muscular dystrophies |
| 02/24/2005 | US20050043220 Methods and compositions for treating macular degeneration |
| 02/24/2005 | US20050043219 Derivatized oligonucleotides having improved uptake and other properties |
| 02/24/2005 | US20050043218 Gene therapy for accelerating the post-chemotherapy peripheral blood cell recovery; removal of hematopoietic cells, transfection, ex vivo contact with an amino acid sequence from a chain of hemoglobin, transplanting the cells back into the patient |
| 02/24/2005 | US20050043217 Stabilized compositions containing an oxygen-labile active agent and lactoglobulin |
| 02/24/2005 | US20050043216 Enamel matrix proteins administered topically as antineoplastic agents for ovarian, glandular, skin, muscle, or bone tumors. |
| 02/24/2005 | US20050043214 Antiglaucomatous agent and use thereof |
| 02/24/2005 | US20050043213 Inhibiting secondary amide peptide bond cis/trans isomerases (APIases); screening for enzyme inhibitors; anticarcinogenic, antiproliferative agents; hyperplasia |
| 02/24/2005 | US20050042738 Carbohydrate-associated proteins |
| 02/24/2005 | US20050042731 Four helical bundle cytokine family polypeptide for use in treatment, diagnosis and prevention of infection, cardiovascular, metabolic, developmental, skin, bone, inflammatory and autoimmune disorders |
| 02/24/2005 | US20050042729 Expression vector comprising nucleotide sequences conding immunoglobulin/interferon fusion for use in targeting and treatment of liver disorders |
| 02/24/2005 | US20050042724 Sodium-dependent phosphate cotransporter (NAPTR) for use tool in identifying modulators for treatment and prevention of cell proliferative, nervous system and cardiovascular disorders |
| 02/24/2005 | US20050042714 Glycoconjugates of sialic acid derivates, methods for their production and use thereof |
| 02/24/2005 | US20050042706 Methods for the identification of inhibitors of porphobilinogen deaminase as antibiotics |
| 02/24/2005 | US20050042699 Cardiotrophin-1 compositions and methods for the treatment of tumor |
| 02/24/2005 | US20050042687 Methods and compositions for treating hematological disorders using 9118, 990, 17662, 81982, 630, 21472, 17692, 19290, 21620, 21689, 28899, 53659, 64549, 9465, 23544, 7366, 27417, 57259, 21844, 943, 2061, 5891, 9137, 13908, 14310, 17600, 25584, 27824, 28469, 38947, 53003, 965, 56639, 9661, 16052, 1521, 6662, 13913, 12405 or 5014 |
| 02/24/2005 | US20050042683 Expression vector comprising nucleotide sequences coding serum response element receptor (SERB-2) for use in identifying modulator for prevention and treatment of nervous system disorders |
| 02/24/2005 | US20050042671 Modulation of angiogenesis |
| 02/24/2005 | US20050042667 Expression vector comprising nucleotide sequences coding polypeptide for use in diagnosis, treatment and prevention of immune, hematopoietic, inflammatory and tumor diseases |
| 02/24/2005 | US20050042659 Secreted soluble alpha2delta-2, alpha2delta-3, or alpha2delta-4 calcium channel subunit polypeptides and screening assays using same |
| 02/24/2005 | US20050042655 Using hematopoietoic regulatory related polypeptide (HEMA) for use in diagnosis, treatment and prevention of hematopoietic disorders |
| 02/24/2005 | US20050042653 Human transport protein homologs |
| 02/24/2005 | US20050042652 Identifying monoclonal antibody for use in prevention and treatment of skin disorers; immunotherapy and peptide mimetics |
| 02/24/2005 | US20050042646 RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
| 02/24/2005 | US20050042637 Pax-encoding vector and use thereof |
| 02/24/2005 | US20050042635 Prophylactic and therapeutic benefits of a new class of immune stimulating peptides |
| 02/24/2005 | US20050042631 Cloning and characterization of two novel m-RNA transcription factors |
| 02/24/2005 | US20050042614 Point mutations; dipeptidyl-peptidase inhibitors; kits |
| 02/24/2005 | US20050042602 Monitoring immunologic, Hematologic and inflammatory diseases |
| 02/24/2005 | US20050042315 Paget's disease; antitumor agents; osteoporesis; nutrient mixture of plant extract and calcium compound |
| 02/24/2005 | US20050042300 Use of colostrinin, constituent peptides thereof, and analogs thereof as inhibitors of apoptosis and other cellular damage |
| 02/24/2005 | US20050042299 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection |
| 02/24/2005 | US20050042295 Anti-angiogenic compositions and methods of use |
| 02/24/2005 | US20050042294 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 02/24/2005 | US20050042273 Covalently linking PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex; diagnostic and therapeutic agent; improving pharmacokinetic properties |
| 02/24/2005 | US20050042252 Mixture apatite and collagen; crosslinking with glutaraldehyde; ; bones; osteoporosis |
| 02/24/2005 | US20050042237 Method for administering a spill resistant pharmaceutical system |
| 02/24/2005 | US20050042236 Plant extract active as an immunostimulating agent |
| 02/24/2005 | US20050042228 Method and pharmaceutical composition for the treatment of immune disorders |
| 02/24/2005 | US20050042227 drug biological conjugates used in the diagnosis, prophylaxis, or treatment of nervous system disorders or lysosomal storage diseases; drug delivery; blood brain barriers |
| 02/24/2005 | US20050042224 Methods and products related to metabolic interactions in disease |
| 02/24/2005 | US20050042222 Methods of diagnosing thyroid carcinoma |
| 02/24/2005 | US20050042220 Antigen binding fragments; rheumatoid arthritis, osteoarthritis, multiple sclerosis, myasthenia gravis, Crohn*s disease, inflammatory bowel disease, lupus, diabetes, psoriasis, asthma, chronic obstructive pulmonary disease, cardiovascular inflammation, pancreatitis, hepatitis, and nephritis |
| 02/24/2005 | US20050042217 Contacting a target cell expressing target cell-specific antigen with an expression vector encoding a CD8 polypeptide comprising the CD8 alpha -chain; extending survival of transplant allografts and treating graft versus host disease |
| 02/24/2005 | US20050042213 Administering rhodanine derivative and O,O*-dihydroxybenzenebis(p-amidophenol) derivative; metabolic, neurodegenerative and autoimmune diseases; wound healing, antiinflammatory, and anticarcinogenic agents; atherosclerosis, restenosis, nephropathy |
| 02/24/2005 | US20050042212 Method of reducing CRF receptor mRNA |
| 02/24/2005 | US20050042209 Enhancing the induction apoptosis in a MUC1 expressing cancer cell by a pro-apoptotic drugs; antiproliferative agents |
| 02/24/2005 | US20050042206 Viral vectors having reduced virulence |
| 02/24/2005 | US20050042205 Purification and cloning of receptors for luteinizing hormone, choriogonadotropin, follicle stimulating hormone, and/or thyroid stimulating hormone; fertility, breast or prostate cancer, benign prostatic hypertrophy, vasomotor instability, osteoporosis, and polycystic ovarian disease; genetic engineering |
| 02/24/2005 | US20050042202 Gentamicin, amikacin, tobramycin, netilmicin, cephalosporin, ceftazidine, maxalactam, carbopenem, imipenem, aztreonam, ampicillin, penicillin, ureidopenicillin, augmentin, amphotericin, famvir and/or acyclovir; and Vpr protein, fragment or nucleic acid encoding; systemic inflammatory response syndrome |
| 02/24/2005 | US20050042201 Synergistic mixture of glycoprotein and angiogenesis inhibitor comprising angiostatin, thrombostatin, endostatin, interferon, interferon-inducible factor 10, platelet factor, and/or cyclooxygenase inhibitor; antitumor and anticarcinogenic agents |
| 02/24/2005 | US20050042200 Administering to mammal interleukin-11 to increase leptin levels; free of dividing adipocytes; obesity and diabetes treatment |
| 02/24/2005 | US20050042199 Comprising interleukin-2 (IL-2) and tlp peptides ( Tumour Liberated Particles) protein complexes; antitumor and anticarcinogenic agents; immunotherapy |
| 02/24/2005 | DE10334777A1 New antiproliferative peptide, useful for treating tumors, atherosclerosis or psoriasis, comprises a segment that mediates binding to extracellular matrix and a nuclear localization sequence |
| 02/24/2005 | DE10333240A1 Therapy for traumatic injuries or coronary conditions involves use of immunosuppressives or ethyl alcohol infusions, each in addition to conventional therapies |
| 02/24/2005 | DE10333192A1 Pharmazeutischer Wirkstoff gegen Warzen, Herpes simplex und Herpes zoster Active pharmaceutical ingredient against warts, herpes simplex and herpes zoster |
| 02/24/2005 | CA2762015A1 Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| 02/24/2005 | CA2575926A1 Canine specific growth hormone releasing hormone |
| 02/24/2005 | CA2536235A1 Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |